Drug-coated Balloons vs. Drug Eluting Stents in Bifurcation Coronary Lesions: PICCOLETO V Study

Status: Recruiting
Location: See all (17) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is an investigator-driven prospective, multicentric, international, randomized clinical study, in an open-label randomized fashion, where patients with bifurcation coronary artery disease (Medina: 111,101,011,001) in vessels with diameter \>2.0 (visual estimation) and with a clinical indication to PCI, will be enrolled. After successful predilatation (with any tool deemed useful), patients will be randomized 1:1:1 to SCB, PCB or standard treatment with DES for bifurcation native vessel disease. All patients with a clinical indication for PCI, both stable coronary artery disease and acute coronary syndrome, will be enrolled. Before participating all the candidates will be clearly informed about the study, including the possible risks and benefits, and will be asked to provide a written informed consent. Subjects will be instructed that may not meet the general criteria for inclusion or the angiographic criteria, or that may have at least one exclusion criteria, and then be excluded from the study (screening failure), even after informed consent is obtained. Consecutive patients who meet at least one of the inclusion criteria and none of the exclusion criteria, will participate to the study. After randomization, the procedure will consist in standard coronary angioplasty following international guidelines/consensus documents and as per local practice. If the patient has been randomized to SCB or PCB, it is mandatory to adequately prepare the lesion.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject must be age ≥18 years.

• Subject has silent ischemia, or stable/unstable angina, or acute MI older than 1-week from the onset of chest pain to admission.

• Subject understands the trial design and treatment procedures and provides written informal consent before entering the trial

• Subject is willing to comply with all protocol-required follow-up evaluations.

• Target lesion must be native non-LM bifurcation lesion

• Target lesion must be a bifurcation lesion on coronary angiography (defined as Medina 0,1,1, Medina 1,0,1, Medina 1,1,1 or Medina 0,0,1 coronary bifurcation lesions) and is eligible for percutaneous coronary intervention (PCI).

• Target lesion reference vessel diameter (both main vessel and side branch)

⁃ 2.0 mm by visual estimation.

• Target lesion must have visually estimated stenosis ≥50%.

• Target lesion length of side branch must be \<25 mm by visual estimation.

Locations
Other Locations
Italy
Fondazione Ricerca e Innovazione Cardiovascolare
NOT_YET_RECRUITING
Milan
Poland
First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
NOT_YET_RECRUITING
Gdansk
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
NOT_YET_RECRUITING
Katowice
Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
NOT_YET_RECRUITING
Krakow
Second Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
NOT_YET_RECRUITING
Krakow
Department of Cardiology, Copper Health Centre (MCZ)
NOT_YET_RECRUITING
Lubin
Clinical Department of Interventional Cardiology, Medical University of Lublin
NOT_YET_RECRUITING
Lublin
Department of Cardiology, Poznan University of Medical Sciences
NOT_YET_RECRUITING
Poznan
Department of Cardiology, The Ministry of Internal Affairs and Administration Hospital, Rzeszow
NOT_YET_RECRUITING
Rzeszów
Department of Cardiology
NOT_YET_RECRUITING
Wałbrzych
Department of Cardiology and Internal Diseases, Military Institute of Medicine
NOT_YET_RECRUITING
Warsaw
Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration
NOT_YET_RECRUITING
Warsaw
Centre for Heart Disease, University Hospital Wroclaw Department of Heart Disease, Wroclaw Medical University
NOT_YET_RECRUITING
Wroclaw
Third Department of Cardiology, Medical University of Katowice
NOT_YET_RECRUITING
Zabrze
Romania
Heart Institute, Cluj-Napoca
RECRUITING
Cluj-napoca
Sibiu County Emergency Clinical Hospital
RECRUITING
Sibiu
Singapore
Tan Tock Seng Hospital
NOT_YET_RECRUITING
Singapore
Contact Information
Primary
Bernardo Cortese
bcortese@gmail.com
504827636
Backup
Wojciech Wańha
wojciech.wanha@gmail.com
504827636
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2028-02-01
Participants
Target number of participants: 321
Treatments
Experimental: Device: Paclitaxel drug-coated-balloons
Experimental: Device: Sirolimus drug-coated-balloons
Active_comparator: Device: new generation drug-eluting-stents
Sponsors
Leads: Fondazione Ricerca e Innovazione Cardiovascolare ETS

This content was sourced from clinicaltrials.gov